Skip to main content

Table 1 Patient characteristics

From: TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival

  Sporadic cases BRCA1 carriers
   All familial cases 1135insA 1675delA
No of cases 100 30 10 20
Age at diagnosis: Median 59 49 52.5 47
range 39 – 80 39 – 80 41 – 80 39 – 65
FIGO stage     
I – II 9 (9.0%) 8 (26.7%) 2 (20.0%) 6 (30.0%)
III 65 (65.0%) 14 (46.7%) 5 (50.0%) 9 (45.0%)
IV 26 (26.0%) 8 (26.7%) 3 (30.0%) 5 (25.0%)
Histology     
Serous 82 (82.0%) 24 (80.0%) 7 (70.0%) 17 (85.0%)
Mixed 7 (7.0%) 2 (6.6%) 1 (10.0%) 1 (5.0%)
Endometroid 5 (5.0%) 3 (10.0%) 1 (10.0%) 2 (10.0%)
Unclassified 6 (6.0%) 1 (3.3%) 1 (10.0%) 0
Grade of differentiation     
1 7 (7.0%) 0 0 0
2 26 (26.0%) 5 (16.6%) 1 (10.0%) 4 (20.0%)
3 67 (67.0%) 24 (80.0%) 9 (90.0%) 15 (75.0%)
Unknown 0 1 (3.3%) 0 1 (5.0%)
Survival >5 years 23 (23.0%) 10 (33.3%) 3 (30.0%) 7 (35.0%)
TP53 mutation status 72.0% 53.3% 50.0% 55.0%
  1. All tumors are epithelial adenocarcinomas
\